One of the world's largest medical testing companies, Labcorp runs thousands of patient service centers and supports drug development trials for biopharma clients around the globe, offering everything from routine blood work to oncology and prenatal screening. It began in 1969, when three brothers—the Powells—started testing specimens in the former laundry room of a North Carolina hospital; that lab merged with National Health Laboratories in 1995 to create today's company.
Labcorp Q2 2026 operating income rose 14.5% to $451.6M as both Dx and BLS margins expanded.
Both Labcorp segments expanded margins this quarter. rose 5.8% to $3.73B and climbed 28.2% to $3.64, driven by of 4.2% and a lower tax rate from a foreign entity restructuring. The company is growing profitably, but fell 42.2% as acquisition spending rose.
Key takeaways
rose 14.5% to $451.6M as Diagnostics (Dx) expanded 50 to 18.0% and (BLS) margin expanded 130 basis points to 17.0%.
grew 5.8% to $3,731.1M, with of 4.2%, acquisitions net of divestitures contributing 1.2%, and favorable currency translation adding 0.4%.
Dx increased 5.5% to $2,900.7M on 3.0% volume growth and 2.5% price/mix improvement; BLS revenue rose 6.5% to $836.2M on 6.2% driven by Central Laboratory performance and efficiencies.
Section summaries
Management's Discussion and Analysis
Labcorp Q2 FY2026 revenue rose 5.8% to $3.73B on organic growth and acquisitions, with margin expansion in both Dx and BLS segments.
⌄
Total Q2 grew 5.8% to $3,731.1M, driven by 4.2% , 1.2% from acquisitions net of divestitures, and 0.4% from currency.
rose 28.2% to $3.64, helped by a lower of 13.1% versus 22.6% a year ago, primarily from discrete benefits of tax restructuring of certain foreign entities.
Cost of revenues improved to 70.2% of from 71.2% and SG&A leveraged to 15.5% from 17.3%, both benefiting from revenue growth and operating efficiencies.
fell 42.2% to $313.9M as and acquisition spending increased; the company entered a $750M term loan and redeemed 2026 senior notes.
What changed
The PAMA-mandated $100M Medicare reimbursement reduction flagged in prior filings took effect in 2026, yet Dx margin expanded 50 to 18.0% this quarter, up from 16.6% in Q1 2026, suggesting the cut was absorbed through volume growth and operating efficiencies.
Dx organic volume growth was 1.8% this quarter, up from 1.1% in Q1 2026 but still well below the 11.8% rate from 2023 that earlier filings had flagged to watch.
BLS of 6.2% moderated from 7.8% in Q2 2025 but remained above the 4.0% full-year 2025 rate, with the currency shrinking to 0.3% from 3.2% a year ago.
of $445.5M fell 28.2% , a reversal from the 10.6% increase in Q2 2025, as higher cash earnings were offset by changes.
rose 15.4% to $5,857.6M after the company entered a $750M term loan, while cash and equivalents fell 78.1% to $141.8M, the lowest quarter-end balance since Q1 2024.
What to watch
Q3 2026 Dx organic volume growth to see if the 1.8% rate continues to improve or stalls below the 's historical growth trajectory.
Q3 2026 after Q2 fell 28.2% to $445.5M, to see if the decline is a one-quarter shift or a trend.
Use of the $750M term loan proceeds and the $1.0B against upcoming debt maturities, with cash at $141.8M.
Whether the 13.1% from foreign entity restructuring is a one-time benefit or signals a sustainably lower rate.
Diagnostics () increased 5.5% to $2,900.7M on 3.0% volume growth (1.8% organic) and 2.5% price/mix improvement; Dx expanded 50 to 18.0%.
Biopharma Laboratory Services () rose 6.5% to $836.2M on 6.2% , with up 130 to 17.0% driven by Central Laboratory performance and ED efficiencies.
Cost of revenues improved 10 to 70.2% of , while leveraged 90 bps to 15.5%, both benefiting from revenue growth and operating efficiencies despite higher personnel costs.
was $637.0M for H1 2026, slightly below prior year; investing outflows rose to $688.3M on higher M&A and ; the company entered a $750M term loan and redeemed 2026 senior notes.
The company announced a $0.72/share quarterly and increased its authorization to $1,378.6M; it expects sufficient liquidity from cash flow and credit facilities.
Quantitative and Qualitative Disclosures About Market Risk
Foreign exchange and interest rate risks are managed via forwards, cross-currency swaps, and interest rate swaps; a 10% FX move could impact pre-tax income by ~$17.1M.
⌄
About 13.9% of H1 2026 was non-USD, with the largest exposures to CAD, CHF, EUR, and GBP.
A hypothetical 10% adverse shift in average foreign exchange rates would affect pre-tax income by approximately $17.1 million over the six months ended June 30, 2026.
The company hedges net investment exposure via USD/CHF cross-currency swaps totaling $1.2 billion notional, maturing between 2029 and 2034.
At quarter-end, the company held 10 foreign exchange forward contracts with a total of about $424.1 million to limit transaction risk.
Variable-rate debt of $750.0 million (2026 Term Loan) and $550.0 million () is outstanding; each quarter-point rate change moves annual by roughly $3.3 million.
Interest rate risk is partially managed through fixed-to-variable interest rate swaps on $500.0 million notional of 2.70% senior notes due 2031, referencing compounded plus 1.33%.